CEFPODOXIME PROXETIL

Cefpodoxime Proxetil Adverse Events Reported to the FDA Over Time

How are Cefpodoxime Proxetil adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cefpodoxime Proxetil, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cefpodoxime Proxetil is flagged as the suspect drug causing the adverse event.

Most Common Cefpodoxime Proxetil Adverse Events Reported to the FDA

What are the most common Cefpodoxime Proxetil adverse events reported to the FDA?

Pyrexia	39 (2.31%)
Diarrhoea	31 (1.84%)
Pruritus	31 (1.84%)
Vomiting	27 (1.6%)
Asthenia	22 (1.3%)
Thrombocytopenia	22 (1.3%)
Clostridium Difficile Colitis	20 (1.18%)
Renal Failure Acute	19 (1.13%)
Drug Exposure During Pregnancy	18 (1.07%)
Purpura	18 (1.07%)
Rash	17 (1.01%)
	Show More
Stevens-johnson Syndrome	16 (.95%)
Haemolytic Anaemia	14 (.83%)
Pancreatitis Acute	14 (.83%)
Toxic Epidermal Necrolysis	14 (.83%)
Angioedema	13 (.77%)
Dehydration	13 (.77%)
Erythema Multiforme	13 (.77%)
Arthralgia	12 (.71%)
Eosinophilia	12 (.71%)
Headache	12 (.71%)
White Blood Cell Count Increased	12 (.71%)
Abdominal Pain	11 (.65%)
Hepatitis	11 (.65%)
Jaundice	11 (.65%)
Agranulocytosis	10 (.59%)
Hepatitis Cholestatic	10 (.59%)
Intra-uterine Death	10 (.59%)
Urticaria	10 (.59%)
Cough	9 (.53%)
Liver Disorder	9 (.53%)
Pallor	9 (.53%)
Pseudomembranous Colitis	9 (.53%)
Spina Bifida	9 (.53%)
Toxic Skin Eruption	9 (.53%)
Alanine Aminotransferase Increased	8 (.47%)
Aspartate Aminotransferase Increase...	8 (.47%)
C-reactive Protein Increased	8 (.47%)
Conjunctival Hyperaemia	8 (.47%)
Dermatitis Exfoliative	8 (.47%)
Dizziness	8 (.47%)
Drug Interaction	8 (.47%)
Epistaxis	8 (.47%)
Galactorrhoea	8 (.47%)
Haematuria	8 (.47%)
Heart Rate Increased	8 (.47%)
Infection	8 (.47%)
Malaise	8 (.47%)
Nephrotic Syndrome	8 (.47%)
Oedema Peripheral	8 (.47%)
Stillbirth	8 (.47%)
Burning Sensation	7 (.41%)
Cheilitis	7 (.41%)
Fall	7 (.41%)
Gamma-glutamyltransferase Increased	7 (.41%)
Insomnia	7 (.41%)
Overdose	7 (.41%)
Paraesthesia	7 (.41%)
Rash Maculo-papular	7 (.41%)
Arnold-chiari Malformation	6 (.36%)
Balance Disorder	6 (.36%)
Blister	6 (.36%)
Dysphagia	6 (.36%)
Ecchymosis	6 (.36%)
Eye Discharge	6 (.36%)
Haematoma	6 (.36%)
Hyperprolactinaemia	6 (.36%)
International Normalised Ratio Incr...	6 (.36%)
Leukocytosis	6 (.36%)
Lymphadenitis	6 (.36%)
Myalgia	6 (.36%)
Neutrophil Count Increased	6 (.36%)
Normochromic Normocytic Anaemia	6 (.36%)
Ocular Hyperaemia	6 (.36%)
Otitis Media	6 (.36%)
Pneumonia	6 (.36%)
Rash Erythematous	6 (.36%)
Renal Tubular Necrosis	6 (.36%)
Skin Lesion	6 (.36%)
Visual Field Defect	6 (.36%)
Blood Bilirubin Increased	5 (.3%)
Bronchitis	5 (.3%)
Cardiomegaly	5 (.3%)
Clostridial Infection	5 (.3%)
Confusional State	5 (.3%)
Convulsion	5 (.3%)
Diplopia	5 (.3%)
Drug Ineffective	5 (.3%)
Erythema	5 (.3%)
Gastroenteritis	5 (.3%)
Gastrointestinal Disorder	5 (.3%)
Haemolytic Uraemic Syndrome	5 (.3%)
Hepatic Fibrosis	5 (.3%)
Hepatitis Acute	5 (.3%)
Hypogammaglobulinaemia	5 (.3%)
Hypokalaemia	5 (.3%)
Hyponatraemia	5 (.3%)
Inflammation	5 (.3%)
Kidney Enlargement	5 (.3%)
Lymphocyte Count Decreased	5 (.3%)
Nausea	5 (.3%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Cefpodoxime Proxetil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cefpodoxime Proxetil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cefpodoxime Proxetil

What are the most common Cefpodoxime Proxetil adverse events reported to the FDA?

Epidermal And Dermal Conditions	163 (9.66%)
Hepatic And Hepatobiliary	76 (4.5%)
Hematology Investigations	73 (4.32%)
Gastrointestinal Signs	60 (3.55%)
Infections - Pathogen Unspecified	49 (2.9%)
Neurological	49 (2.9%)
Bacterial Infectious	45 (2.67%)
Body Temperature Conditions	39 (2.31%)
Hepatobiliary	38 (2.25%)
White Blood Cell	37 (2.19%)
Gastrointestinal Motility And Defec...	36 (2.13%)
	Show More
Renal Disorders	35 (2.07%)
Respiratory	32 (1.9%)
Skin Vascular Abnormalities	32 (1.9%)
Platelet	29 (1.72%)
Ocular Infections, Irritations And ...	28 (1.66%)
Hemolyses And Related Conditions	24 (1.42%)
Angiedema And Urticaria	23 (1.36%)
Electrolyte And Fluid Balance Condi...	23 (1.36%)
Abortions And Stillbirth	22 (1.3%)
Chemical Injury And Poisoning	22 (1.3%)
Medication Errors	20 (1.18%)
Urinary Tract Signs	20 (1.18%)
Oral Soft Tissue Conditions	19 (1.13%)
Muscle	18 (1.07%)
Neurological Disorders Congenital	17 (1.01%)
Anemias Nonhemolytic And Marrow Dep...	16 (.95%)
Exocrine Pancreas Conditions	15 (.89%)
Injuries	15 (.89%)
Therapeutic And Nontherapeutic Effe...	15 (.89%)
Vision	14 (.83%)
Joint	13 (.77%)
Headaches	12 (.71%)
Gastrointestinal Inflammatory Condi...	11 (.65%)
Microbiology And Serology	11 (.65%)
Sleep Disorders	11 (.65%)
Allergic Conditions	10 (.59%)
Hematological And Lymphoid Tissue T...	10 (.59%)
Musculoskeletal And Connective Tiss...	10 (.59%)
Spleen, Lymphatic And Reticulendoth...	10 (.59%)
Vascular	10 (.59%)
Cardiac And Vascular Investigations	9 (.53%)
Nephropathies	9 (.53%)
Protein And Chemistry Analyses	9 (.53%)
Upper Respiratory Tract Disorders	9 (.53%)
Breast	8 (.47%)
Cranial Nerve Disorders	8 (.47%)
Gastrointestinal Conditions	8 (.47%)
Renal And Urinary Tract Investigati...	8 (.47%)
Tongue Conditions	8 (.47%)
Vascular Hemorrhagic	8 (.47%)
Appetite And General Nutritional	7 (.41%)
Gastrointestinal Hemorrhages	7 (.41%)
Gastrointestinal Ulceration And Per...	7 (.41%)
Immunology And Allergy	7 (.41%)
Neurological Disorders Of The Eye	7 (.41%)
Obstetric And Gynecological Therape...	7 (.41%)
Red Blood Cell	7 (.41%)
Seizures	7 (.41%)
Enzyme	6 (.36%)
Hypothalamus And Pituitary Gland	6 (.36%)
Inner Ear And Viiith Cranial Nerve	6 (.36%)
Myocardial	6 (.36%)
Viral Infectious	6 (.36%)
Deliria	5 (.3%)
Gallbladder	5 (.3%)
Glucose Metabolism Disorders	5 (.3%)
Immunodeficiency Syndromes	5 (.3%)
Metabolic, Nutritional And Blood Ga...	5 (.3%)
Mood Disorders	5 (.3%)
Movement Disorders	5 (.3%)
Peritoneal And Retroperitoneal Cond...	5 (.3%)
Physical Examination Topics	5 (.3%)
Pigmentation	5 (.3%)
Procedural And Device Related Injur...	5 (.3%)
Cardiac Arrhythmias	4 (.24%)
Connective Tissue Disorders	4 (.24%)
Demyelinating	4 (.24%)
Disturbances In Thinking	4 (.24%)
Gastrointestinal Tract Disorders Co...	4 (.24%)
Neonatal And Perinatal Conditions	4 (.24%)
Personality Disorders	4 (.24%)
Pleural	4 (.24%)
Psychiatric And Behavioural Symptom...	4 (.24%)
Renal And Urinary Tract Neoplasms M...	4 (.24%)
Salivary Gland Conditions	4 (.24%)
Water, Electrolyte And Mineral	4 (.24%)
Bone Disorders	3 (.18%)
Dental And Gingival Conditions	3 (.18%)
Fatal Outcomes	3 (.18%)
Fungal Infectious	3 (.18%)
Hepatobiliary Neoplasms Malignant A...	3 (.18%)
Immune System Disorders Congenital	3 (.18%)
Increased Intracranial Pressure And...	3 (.18%)
Lower Respiratory Tract Disorders	3 (.18%)
Lymphomas Non-hodgkins T-cell	3 (.18%)
Pericardial	3 (.18%)
Placental, Amniotic And Cavity Diso...	3 (.18%)
Pregnancy, Labour, Delivery And Pos...	3 (.18%)
Respiratory And Pulmonary Investiga...	3 (.18%)
Skin And Subcutaneous Tissue	3 (.18%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cefpodoxime Proxetil, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cefpodoxime Proxetil is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.